T. Rowe Price Investment Management Inc. Has $2.24 Billion Stake in Abbott Laboratories $ABT

T. Rowe Price Investment Management Inc. increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,887,109 shares of the healthcare product maker’s stock after buying an additional 118,014 shares during the period. Abbott Laboratories comprises approximately 1.4% of T. Rowe Price Investment Management Inc.’s portfolio, making the stock its 10th largest position. T. Rowe Price Investment Management Inc.’s holdings in Abbott Laboratories were worth $2,241,076,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABT. Compound Planning Inc. raised its stake in shares of Abbott Laboratories by 53.5% during the fourth quarter. Compound Planning Inc. now owns 37,315 shares of the healthcare product maker’s stock valued at $4,675,000 after acquiring an additional 13,010 shares during the last quarter. Claris Financial LLC acquired a new stake in Abbott Laboratories in the fourth quarter valued at $307,000. ATX Financial Planning LLC bought a new position in Abbott Laboratories during the 4th quarter worth $1,342,000. Evansbrook LLC acquired a new position in Abbott Laboratories during the 4th quarter worth about $414,000. Finally, Axxcess Wealth Management LLC lifted its holdings in Abbott Laboratories by 0.5% during the 4th quarter. Axxcess Wealth Management LLC now owns 140,663 shares of the healthcare product maker’s stock worth $17,624,000 after buying an additional 665 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ABT. Weiss Ratings cut Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday. Citigroup decreased their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, April 17th. JPMorgan Chase & Co. reduced their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Raymond James Financial dropped their target price on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Wells Fargo & Company lowered their price objective on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $118.30.

Abbott Laboratories Stock Down 0.0%

Shares of NYSE ABT opened at $88.48 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm has a market cap of $154.12 billion, a PE ratio of 24.78, a P/E/G ratio of 1.52 and a beta of 0.63. The company’s fifty day simple moving average is $90.39 and its 200 day simple moving average is $106.73. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.